查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1552698

非肌肉浸潤性膀胱癌市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2024-2034 年

Non-muscle Invasive Bladder Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 165 Pages | 商品交期: 2-10個工作天內

價格

非肌肉浸潤性膀胱癌市場 - 報告範圍

TMR 關於全球非肌肉層浸潤性膀胱癌市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2024 年至2034 年預測期內市場指標的寶貴見解。膀胱癌市場的收入2018-2034年期間非肌肉層浸潤性膀胱癌市場，考慮2024年為基準年，2034年為預測年。報告中也提供了2024年至2034年全球非肌肉層浸潤性膀胱癌市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解非肌肉層浸潤性膀胱癌市場。

市場概況
2023年市場價值 26 億美元
2034 年市場價值 211 億美元
複合年成長率 21.4%

該報告深入研究了全球非肌肉層浸潤性膀胱癌市場的競爭格局。全球非肌肉層浸潤性膀胱癌市場的主要參與者已經確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球非肌肉浸潤性膀胱癌市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依治療類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依治療類型，2020-2034
    • 免疫治療
    • 化療
    • 標靶治療
  • 市場吸引力分析：按治療類型

第 7 章：全球市場分析與預測：按癌症類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按癌症類型，2020-2034
    • 低度膀胱癌
    • 高級別膀胱癌
  • 市場吸引力分析：按癌症類型

第 8 章：全球市場分析與預測：按配銷通路

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2020-2034
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 市場吸引力分析：按配銷通路

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • Liminal BioSciences Inc.
    • TARIS Biomedical LLC
    • Merck & Co., Inc.
    • Herantis Pharma Oyj
    • Viventia Bio Inc.
    • Telormedix SA
    • Ferring BV
    • Altor BioScience Corporation
    • Novartis AG
    • Pfizer Inc.
    • GSK plc
    • Sanofi SA
    • Eli Lilly and Company
    • AstraZeneca
Product Code: TMRGL86334

Non-muscle Invasive Bladder Cancer Market - Scope of Report

TMR's report on the global non-muscle invasive bladder cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-muscle invasive bladder cancer market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-muscle invasive bladder cancer market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-muscle invasive bladder cancer market.

Market Snapshot
Market Value in 2023US$ 2.6 Bn
Market Value in 2034US$ 21.1 Bn
CAGR21.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-muscle invasive bladder cancer market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-muscle invasive bladder cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-muscle invasive bladder cancer market.

The report delves into the competitive landscape of the global non-muscle invasive bladder cancer market. Key players operating in the global non-muscle invasive bladder cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-muscle invasive bladder cancer market profiled in this report.

Key Questions Answered in Global non-muscle invasive bladder cancer Market Report:

  • What is the sales/revenue generated by non-muscle invasive bladder cancer across all regions during the forecast period?
  • What are the opportunities in the global non-muscle invasive bladder cancer market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Non-muscle Invasive Bladder Cancer Market - Research Objectives and Research Approach

The comprehensive report on the global non-muscle invasive bladder cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-muscle invasive bladder cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-muscle invasive bladder cancer market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Non-muscle Invasive Bladder Cancer Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 6.3.1. Immunotherapy
    • 6.3.2. Chemotherapy
    • 6.3.3. Targeted Therapy
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Cancer Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Cancer Type, 2020-2034
    • 7.3.1. Low Grade Bladder Cancer
    • 7.3.2. High Grade Bladder Cancer
  • 7.4. Market Attractiveness Analysis, by Cancer Type

8. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 10.3.1. Immunotherapy
    • 10.3.2. Chemotherapy
    • 10.3.3. Targeted Therapy
  • 10.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 10.4.1. Low Grade Bladder Cancer
    • 10.4.2. High Grade Bladder Cancer
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Treatment Type
    • 10.7.2. By Cancer Type
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.3.1. Immunotherapy
    • 11.3.2. Chemotherapy
    • 11.3.3. Targeted Therapy
  • 11.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 11.4.1. Low Grade Bladder Cancer
    • 11.4.2. High Grade Bladder Cancer
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Treatment Type
    • 11.7.2. By Cancer Type
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.3.1. Immunotherapy
    • 12.3.2. Chemotherapy
    • 12.3.3. Targeted Therapy
  • 12.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 12.4.1. Low Grade Bladder Cancer
    • 12.4.2. High Grade Bladder Cancer
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Treatment Type
    • 12.7.2. By Cancer Type
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.3.1. Immunotherapy
    • 13.3.2. Chemotherapy
    • 13.3.3. Targeted Therapy
  • 13.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 13.4.1. Low Grade Bladder Cancer
    • 13.4.2. High Grade Bladder Cancer
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Treatment Type
    • 13.7.2. By Cancer Type
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.3.1. Immunotherapy
    • 14.3.2. Chemotherapy
    • 14.3.3. Targeted Therapy
  • 14.4. Market Value Forecast, by Cancer Type, 2020-2034
    • 14.4.1. Low Grade Bladder Cancer
    • 14.4.2. High Grade Bladder Cancer
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Treatment Type
    • 14.7.2. By Cancer Type
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Liminal BioSciences Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. TARIS Biomedical LLC
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Merck & Co., Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Herantis Pharma Oyj
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Viventia Bio Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Telormedix SA
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Ferring B.V.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Altor BioScience Corporation
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Novartis AG
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Pfizer Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. GSK plc
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Sanofi S.A.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Eli Lilly and Company
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. AstraZeneca
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview

List of Tables

  • Table 1: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 2: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 3: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 4: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 5: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 6: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 7: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 8: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 9: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 11: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 12: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 15: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 16: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 19: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 20: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 23: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 24: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 1: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 2: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Treatment Type, 2023
  • Figure 3: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Treatment Type, 2023
  • Figure 4: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Cancer Type, 2023
  • Figure 5: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Cancer Type, 2023
  • Figure 6: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 7: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Distribution Channel, 2023
  • Figure 8: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Region, 2023
  • Figure 9: Global Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 11: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 13: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 14: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 22: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 23: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 26: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 31: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 32: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 35: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 40: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 41: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 44: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 49: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 50: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 53: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 58: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 59: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 62: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034